Millendo Therapeutics Inc
Millendo Therapeutics, Inc. Stock, NASDAQ:MLND
Millendo Therapeutics, Inc. engages in the development of treatments for orphan endocrine diseases. Its product pipeline includes Livoletide (AZP-531) for the treatment of Prader-Willi syndrome; Nevanimibe for classic congenital adrenal hyperplasia; and Neurokinin 3 receptor for vasomotor symptoms. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI.